LBPMedicine(SH:688393)2023-04-27 16:00Financial Performance - The company's operating revenue for Q1 2023 was ¥90,744,669.29, representing a decrease of 24.44% compared to the same period last year[5] - The net profit attributable to shareholders for Q1 2023 was ¥7,819,891.42, down 60.15% year-over-year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥2,687,735.93, reflecting an 85.35% decline compared to the previous year[5] - Basic earnings per share for Q1 2023 were ¥0.08, down 61.90% year-over-year[6] - Net profit for Q1 2023 was -¥166,119.75, compared to a net profit of ¥17,321,842.35 in Q1 2022, indicating a significant decline[20] - The total equity attributable to shareholders increased to ¥1,239,186,893.62 in Q1 2023 from ¥1,228,605,285.24 in Q1 2022, showing a growth of about 0.5%[18] Cash Flow - The net cash flow from operating activities was -¥17,959,253.73, a significant decrease of 12,727.15% compared to the same period last year[5] - The company reported a net cash flow from operating activities of -¥17,959,253.73 in Q1 2023, contrasting with a positive cash flow of ¥142,227.31 in Q1 2022[22] - The net cash flow from investing activities was -$1,485,469.38, compared to $91,163,278.99 in the previous period, indicating a significant decrease in investment returns[23] - The cash inflow from financing activities was $3,357,000.00, primarily from minority shareholders' investments, while the net cash flow from financing activities was -$570,776.85, compared to $2,557,074.17 previously[23] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,371,910,263.46, a decrease of 1.50% from the end of the previous year[6] - The company's current assets totaled ¥509,847,262.66, down from ¥595,076,395.73 at the end of 2022, indicating a decline of approximately 14.3%[14] - The total liabilities decreased to ¥146,973,508.56 in Q1 2023 from ¥170,447,006.45 in Q1 2022, reflecting a reduction of approximately 13.7%[18] - The company's total liabilities were not explicitly stated, but current liabilities included accounts payable of ¥30,358,126.25, down from ¥32,591,057.59, a decrease of about 6.8%[15] Research and Development - Research and development expenses totaled ¥14,264,308.12, accounting for 15.72% of operating revenue, an increase of 3.38 percentage points[6] - The company’s research and development expenses for Q1 2023 were ¥12,842,534.61, a decrease of 13.3% from ¥14,813,078.40 in Q1 2022[18] Inventory and Receivables - The company's accounts receivable stood at ¥232,608,440.91, slightly down from ¥236,164,593.91, showing a decrease of approximately 1.3%[14] - Inventory increased to ¥70,909,307.59 from ¥63,073,696.31, representing an increase of about 12.9%[14] Financial Management - The company is actively managing its financial assets, with trading financial assets reported at ¥107,041,708.13, down from ¥175,536,506.82, a decrease of approximately 39.0%[14] - The company has ongoing investments in various non-current financial assets, totaling ¥164,554,562.25, an increase from ¥147,449,916.08[15] Other Financial Metrics - The weighted average return on equity was 0.63%, a decrease of 0.36 percentage points from the previous year[6] - The company reported non-recurring gains totaling ¥5,132,155.49 for the period[7] - Cash received from sales of goods and services was ¥102,350,362.44 in Q1 2023, down from ¥117,195,663.62 in Q1 2022, a decline of 12.7%[22] - The company reported an increase in investment income to ¥384,247.99 in Q1 2023 from ¥1,389,733.77 in Q1 2022, indicating a decrease of 72.4%[18] Accounting Changes - The company has adopted new accounting standards starting in 2023, which may affect the financial statements[23]